HER2-Low Breast Cancer: Current Landscape and Future Prospects

Breast Cancer Targets and Therapy, Journal Year: 2023, Volume and Issue: Volume 15, P. 605 - 616

Published: Aug. 1, 2023

Abstract: More than 50% of breast cancers are currently defined as "Human epidermal growth factor receptor 2 (HER2) low cancer (BC)", with HER2 immunohistochemistry (IHC) scores +1 or +2 a negative fluorescence in situ hybridization (FISH) test. In most studies that compared the clinical and biological characteristics HER2-low BC HER2-negative BC, was not associated unique molecular characteristics, it seems importance these tumors is being docking site for antibody portion drug conjugates (ADCs). Current pathological methods may underestimate proportion BCs express levels due to analytical limitations tumor heterogeneity. this review we summarize contextualize recent literature on cancers, including translational We also challenges assessing expression discuss current future therapeutic landscape tumors. Keywords: HER2-low, ERBB2 low, cancer, targeted therapy, trastuzumab, trastuzumab-deruxtecan, T-DXd

Language: Английский

---

A Novel NanoMIP–SPR Sensor for the Point-of-Care Diagnosis of Breast Cancer

Micromachines, Journal Year: 2023, Volume and Issue: 14(5), P. 1086 - 1086

Published: May 21, 2023

Simple, fast, selective, and reliable detection of human epidermal growth factor receptor 2 (HER2) is utmost importance in the early diagnosis breast cancer to prevent its high prevalence mortality. Molecularly imprinted polymers (MIPs), also known as artificial antibodies, have recently been used a specific tool therapy. In this study, miniaturized surface plasmon resonance (SPR)-based sensor was developed using epitope-mediated HER2-nanoMIPs. The nanoMIP receptors were characterized dynamic light scattering (DLS), zeta potential, Fourier-transform infrared spectroscopy (FT-IR), transmission electron microscopy (TEM), energy-dispersive X-ray (EDX), fluorescent microscopy. average size nanoMIPs determined be 67.5 ± 12.5 nm. proposed novel SPR provided superior selectivity HER2 with limit (LOD) 11.6 pg mL-1 serum. specificity confirmed by cross-reactivity studies P53, serum albumin (HSA), transferrin, glucose. preparation steps successfully employing cyclic square wave voltammetry. nanoMIP-SPR demonstrates great potential for use robust sensitivity, selectivity, specificity.

Language: Английский

---

Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer

ESMO Open, Journal Year: 2024, Volume and Issue: 9(4), P. 102989 - 102989

Published: April 1, 2024

•The DESTINY-Breast04 trial established HER2-low metastatic breast cancer (IHC 1+ or IHC 2+/ISH−) as a targetable disease.•Treating patients without traditional HER2+ tumors with HER2-directed antibody–drug conjugates represents paradigm shift.•Appropriate identification of eligible for T-DXd is paramount.•Novel biopsy to reassess HER2 expression in cases 0 encouraged. Approximately 60% traditionally defined human epidermal growth factor receptor 2 (HER2)-negative cancers express low levels [HER2-low; immunohistochemistry (IHC) 2+/in situ hybridization (ISH)−]. encompass large percentage both hormone receptor-positive (up 85%) and triple-negative 63%) cancers. The that are targetable, leading the approval trastuzumab deruxtecan (T-DXd) first therapy treatment United States Europe. This change clinical landscape results number questions challenges—including those related assessment patient identification—and highlights need careful identify T-DXd. review provides context understanding how respect sample types, scoring reporting status, testing methods assays. It also discusses management important T-DXd-related adverse events. Available evidence supports efficacy any history 2+/ISH− scores; however, future research may further refine population who could benefit from other therapies novel identification. Because can disease progression treatment, variability exists interpretation re-evaluation certain scenarios help more

Language: Английский

---

Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis

World Journal of Surgical Oncology, Journal Year: 2024, Volume and Issue: 22(1)

Published: April 20, 2024

The survival outcomes in HER2-low versus HER2-zero breast cancer (BC) after neoadjuvant chemotherapy (NACT) remain unclear. meta-analysis was conducted to summarize current evidence about the BC.

Language: Английский

---

Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy

Breast Cancer, Journal Year: 2023, Volume and Issue: 30(6), P. 997 - 1007

Published: Aug. 10, 2023

Breast cancers without HER2 amplification but still expressing this membrane protein constitute a new entity called HER2-low tumors. It is important to characterize them in terms of sensitivity treatment and prognosis.To investigate chemosensitivity long-term prognosis early breast cancer (eBC), compared HER2-0 tumors, we retrospectively retrieved clinicopathological characteristics, response treatment, survival data from 511 patients treated for eBC with neoadjuvant chemotherapy (NAC) French center between 2007 2018. Factors associated the achievement pathologic complete (pCR) were studied among hormone receptor positive (HR+) negative (HR-) eBC.A total 280 HR+ (61% HER2-low), 231 HR- (28% HER2-low) included. We found classical factors usually prognosis, both eBC. By uni- multivariable analysis, status (low vs 0) was not independently pCR, either or Relapse free (RFS) overall (OS) significantly different In contrast, RFS OS slightly better by univariable analysis.In NAC, taking into account HR expression subtype other current features, tumors did appear have their counterparts.

Language: Английский

---

Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer according to HER2 Score (Low vs Score 0): A Retrospective Study.

Clinical Breast Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

---

Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis

Breast Cancer Research, Journal Year: 2025, Volume and Issue: 27(1)

Published: March 15, 2025

Currently, the primary methods for detecting HER2 expression levels are immunohistochemistry (IHC) and in situ hybridization (ISH), with traditional standard being a HER2-positive score of 3 + accompanied by ERBB2 gene amplification detected through ISH. However, new entity has recently emerged: HER2-low, defined as IHC 1 or 2 negative HER2-low breast cancer, representing 45–60% all HER2-negative tumors, distinct biological characteristics uncertain responses to conventional HER2-targeted therapies. Recent studies suggest varied clinical outcomes, highlighting need further investigation into impact status on treatment efficacy prognosis. This meta-analysis evaluates difference complete pathological response (pCR), disease-free survival (DFS), overall (OS) between HER2-zero phenotypes. We systematically searched main databases PubMed, Scopus, Web Science articles evaluating women neoadjuvant therapy expressing HER2-zero. computed odds ratios (ORs) hazard (HRs) using DerSimonian Laird random-effect models endpoints, 95% confidence intervals (CIs). assessed heterogeneity I2 statistics. R, version 4.2.3, was used statistical analyses. 38 totaling 70,104 patients were included. The group accounted 61.3% while HR represented 52.4% whole research. In 67,839 women, pCR analyzed, which cohort analysis favored (OR 0.84; CI 0.78–0.90; p = 0.000005; 15%). Subgroup analyses triple-negative cancer (TNBC) also expression, an OR 0.91 (95% 0.83–1.0; < 0.041; 12%) 0.75 0.70–0.81; 0.000001; 0%), respectively. multivariate across patients, both DFS OS outcomes significantly favorable group, 0.8317 0.7036–0.9832; 0.031) 0.806 0.663–0.979; 0.03) OS. Based our findings, is associated higher (pCR) rate compared early-stage other outcomes. These results that should be considered prognostic factor taken account planning future

Language: Английский

---

Risk Factors Associated with Pathological Complete Response and Its Impact on Outcomes in HER2-Low Breast Cancer Patients: A Propensity Score Matching Study

Indian Journal of Surgical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: April 23, 2025

Language: Английский

---

Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis

Breast Cancer Research and Treatment, Journal Year: 2023, Volume and Issue: 204(1), P. 89 - 105

Published: Dec. 8, 2023

Language: Английский

---

Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy

The Breast, Journal Year: 2023, Volume and Issue: 73, P. 103666 - 103666

Published: Dec. 22, 2023

The present study aimed to evaluate the clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy (NAC).

Language: Английский

---